肺动脉高压的治疗进展
New progress in treatment of pulmonary hypertension
李晓晨 1黄玉臣 1刘先胜2
作者信息
- 1. 华中科技大学同济医学院附属同济医院呼吸与危重症医学科,湖北武汉 430030;国家卫健委呼吸系统疾病重点实验室,湖北武汉 430030
- 2. 华中科技大学同济医学院附属同济医院呼吸与危重症医学科,湖北武汉 430030;国家卫健委呼吸系统疾病重点实验室,湖北武汉 430030;山西白求恩医院(山西医学科学院)同济山西医院呼吸与危重症医学科,山西太原 030032
- 折叠
摘要
肺动脉高压(PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右心衰竭甚至死亡.PH是一个重大的全球健康问题,所有年龄段的人群均可发生PH.临床实践中,PH的治疗和管理具有复杂性、异质性、专业性的特点,需要医患共同决策的全方位、整体化、多学科的策略.本文将结合最新国内外指南及高质量临床研究和真实世界数据总结PH的治疗进展.
Abstract
Pulmonary hypertension(PH)is a clinical and pathophysiologic syndrome of elevated pulmonary vascular resistance and pulmonary arterial pressure due to structural or functional changes in the pulmonary vasculature caused by a variety of heterogenic diseases(etiology)and different pathogenic mechanisms,followed by the development of right heart failure or even death.PH is a major global health problem,and it can occur in people of all ages.In clinical practice,the treatment and management of PH is characterized by complexity,heterogeneity,and specialization,and requires an all-en-compassing,holistic,and multidisciplinary strategy of shared decision-making between doctors and patients.This article summarizes the advances in the treatment of PH in the light of the latest national and international guidelines and high-quality clinical studies and real-world data.
关键词
肺动脉高压/治疗/决策Key words
Pulmonary hypertension/Treatment/Decision-making引用本文复制引用
出版年
2024
NETL
NSTL
万方数据